Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial
Authors' conclusion
Trajectories of inflammatory biomarkers showed a pronounced decline after AMI, but Empagliflozin treatment did not impact this decline indicating no central role in blunted systemic inflammation mediating beneficial effects.
Study context
- Population
- Patients after acute MI treated with percutaneous coronary intervention, on standard guideline-recommended therapy
- Participants
- 374 patients
- Comparison
- Empagliflozin 10 mg once daily vs placebo for 26 weeks on top of standard therapy
- Primary endpoint
- Mean change in inflammatory biomarkers (hsCRP, IL-6, neutrophils, leukocytes, NLR, PLR)
- Follow-up
- Baseline to 26 weeks
Methodological detailsinvestigator-initiated, multicentre, double-blind, placebo-controlled, post-hoc subgroup analysis
- Investigator-initiated
- Multicentre
- Double-blind
- Placebo-controlled
- Post-hoc subgroup analysis
Primary result
As reported in the abstract
Mean change in inflammatory biomarkers · week 26
- Mean reduction in IL-6 (p < 0.001)
- 35.1 ± 3.2%
- Mean reduction in high-sensitive c-reactive protein (hsCRP) (p < 0.001)
- 57.4 ± 0.7%
- Mean reduction in neutrophils (p < 0.001)
- 26.1 ± 0.7%
- Mean reduction in leukocytes (p < 0.001)
- 20.5 ± 0.6%
- Mean reduction in neutrophile/lymphocyte ratio (NLR) (p < 0.001)
- 10.22 ± 0.50%
- Mean reduction in platelet to lymphocyte ratio (PLR) (p = 0.006)
- - 2.53 ± 0.92%
Further findings
Baseline inflammatory biomarkers, median (IQR)
- IL-6
- 17.9 pg/mL (9.0-38.7)
- hsCRP
- 18.9 mg/L (11.2-37.1)
- Neutrophil count
- 7.9 x G/L (6.2-10.1)
- Leukocyte count
- 10.8 x G/L (9.1-12.8)
- NLR
- 0.74 (0.67-0.80)
Original publication
Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial. Cardiovasc Diabetol. Published 5 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →